1
|
Lambert M, Zhang Y, Spinazzola J, Widrick J, Conner J, Kunkel L. DMD – ANIMAL MODELS. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
2
|
Zhang Y, Lambert M, Widrick J, Conner J, Spinazzola J, Kunkel L. PRE-CLINICAL DEVELOPMENTS IN NEUROMUSCULAR DISORDERS. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Bendell JC, Lim KH, Burkard ME, Lin JJ, Chae YK, Socinski MA, Khan G, Reckamp KL, Leland S, Plessinger D, Kunkel L, Dotan E, Otterson G, Ou SHI, Patil T, Heymach JV, Kim ES. Abstract PO-003: CRESTONE – Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) Fusions – A phase 2 study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210). Cancer Res 2020. [DOI: 10.1158/1538-7445.panca20-po-003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: NRG1 (Neuregulin-1) gene fusions are rare oncogenic drivers found in 0.2% of solid tumors, including lung, pancreatic, gallbladder, breast, ovarian, colorectal, neuroendocrine, and sarcomas. NRG1 is the predominant ligand of HER3 and to a lesser extent HER4. NRG1 fusion proteins retaining an active EGF-like domain drive tumorigenesis and proliferation through aberrant HER3 activation. Importantly, NRG1 fusions are often mutually exclusive with other known driver alterations. NRG1 fusions have been correlated with worse overall and disease-free survival and poor response to treatment with standard therapies including chemotherapy, PD-(L)1 checkpoint inhibitors and combinations of these agents. Inhibition of HER3 and its dimerization partners represents a rational and novel therapeutic approach for tumors harboring an NRG1 fusion supported by case studies of clinical responses to anti-HER3 antibodies or pan-ERBB (tyrosine kinase inhibitors) TKIs like afatinib. Seribantumab is a fully human IgG2 mAb against HER3 uniquely able to inhibit NRG1-dependent activation of HER3, HER3-HER2 dimerization, and downstream signaling through the PI3K/AKT and MAPK pathways. The clinical safety profile of seribantumab has been well characterized through prior monotherapy and combination studies in over 800 patients. Methods: CRESTONE is an open label, multicenter Phase 2 basket trial of seribantumab in adult patients with NRG1 fusion-positive locally advanced or metastatic solid tumors who have progressed on or are nonresponsive to available therapies. The trial will enroll at least 75 previously treated patients across three cohorts. Cohort 1 (N=55) will include patients who have not received prior treatment with any ERBB targeted therapy. Cohort 2 (up to N=10) will include patients who have progressed after prior treatment which includes ERBB targeted therapy. Cohort 3 (up to N=10) will include patients harboring NRG1 fusions without an EGF-like binding domain. NRG1 fusion status for enrollment will be determined through a local CLIA or similarly accredited molecular assay. NRG1 fusion status for patients in Cohort 1 will be centrally confirmed using an RNA-based NGS assay. This study will evaluate a novel dosing regimen of weekly induction, biweekly consolidation, and Q3W maintenance designed to rapidly achieve steady state levels, optimize exposure, and deliver maximal NRG1 inhibition. The primary endpoint is ORR per RECIST v1.1 by independent radiologic review. Secondary endpoints include duration of response (DoR), safety, PFS, OS, and overall clinical benefit rate. An interim analysis is planned following enrollment of 20 patients in Cohort 1. CRESTONE is open and accruing patients in the United States. Clinical trial information: NCT04383210.
Citation Format: Johanna C. Bendell, Kian-Huat Lim, Mark E. Burkard, Jessica J. Lin, Young Kwang Chae, Mark A. Socinski, Gazala Khan, Karen L. Reckamp, Shawn Leland, Douglas Plessinger, Lori Kunkel, Efrat Dotan, Gregory Otterson, Sai-Hong Ignatius Ou, Tejas Patil, John V. Heymach, Edward S. Kim. CRESTONE – Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) Fusions – A phase 2 study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210) [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2020 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2020;80(22 Suppl):Abstract nr PO-003.
Collapse
Affiliation(s)
| | | | - Mark E. Burkard
- 3University of Wisconsin Carbone Cancer Center, Madison, WI, USA,
| | | | | | | | - Gazala Khan
- 7Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI, USA,
| | | | | | | | | | - Efrat Dotan
- 11Fox Chase Cancer Center, Philadelphia, PA, USA,
| | | | | | - Tejas Patil
- 14University of Colorado Cancer Center, Aurora, CO, USA,
| | | | - Edward S. Kim
- 16Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
| |
Collapse
|
4
|
Vieira N, Assoni A, Elvers I, Alexander M, Eran A, Marshall J, Verjovski-Almeida S, Lindblad-Toh K, Kunkel L, Zatz M. Jagged1 as a modifier of the DMD phenotype: What is next? Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
5
|
Batlevi CL, Kasamon Y, Bociek RG, Lee P, Gore L, Copeland A, Sorensen R, Ordentlich P, Cruickshank S, Kunkel L, Buglio D, Hernandez-Ilizaliturri F, Younes A. ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. Haematologica 2016; 101:968-75. [PMID: 27151994 DOI: 10.3324/haematol.2016.142406] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Accepted: 04/29/2016] [Indexed: 12/27/2022] Open
Abstract
Classical Hodgkin lymphoma treatment is evolving rapidly with high response rates from antibody-drug conjugates targeting CD30 and immune checkpoint antibodies. However, most patients do not achieve a complete response, therefore development of novel therapies is warranted to improve patient outcomes. In this phase II study, patients with relapsed or refractory Hodgkin lymphoma were treated with entinostat, an isoform selective histone deacetylase inhibitor. Forty-nine patients were enrolled: 33 patients on Schedule A (10 or 15 mg oral entinostat once every other week); 16 patients on Schedule B (15 mg oral entinostat once weekly in 3 of 4 weeks). Patients received a median of 3 prior treatments (range 1-10), with 80% of the patients receiving a prior stem cell transplant and 8% of patients receiving prior brentuximab vedotin. In the intention-to-treat analysis, the overall response rate was 12% while the disease control rate (complete response, partial response, and stable disease beyond 6 months) was 24%. Seven patients did not complete the first cycle due to progression of disease. Tumor reduction was observed in 24 of 38 (58%) evaluable patients. Median progression-free survival and overall survival was 5.5 and 25.1 months, respectively. The most frequent grade 3 or 4 adverse events were thrombocytopenia (63%), anemia (47%), neutropenia (41%), leukopenia (10%), hypokalemia (8%), and hypophosphatemia (6%). Twenty-five (51%) patients required dose reductions or delays. Pericarditis/pericardial effusion occurred in one patient after 12 cycles of therapy. Future studies are warranted to identify predictive biomarkers for treatment response and to develop mechanism-based combination strategies. (clinicaltrials.gov identifier: 00866333).
Collapse
Affiliation(s)
| | | | | | - Peter Lee
- Tower Cancer Research Foundation, Beverly Hills, CA, USA
| | - Lia Gore
- University of Colorado Cancer Center, Aurora, CO, USA
| | | | | | | | | | - Lori Kunkel
- Syndax Pharmaceuticals, Inc., Waltham, MA, USA
| | | | | | - Anas Younes
- Memorial Sloan Kettering Cancer Center, New York, NY, USA MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
6
|
Kruger JS, Kodjebacheva GD, Kunkel L, Smith KD, Kruger DJ. Caregiver financial distress, depressive symptoms and limited social capital as barriers to children's dental care in a mid-western county in the United States. Community Dent Health 2015; 32:252-256. [PMID: 26738225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
OBJECTIVE To identify barriers to children's access to dental care. BASIC RESEARCH DESIGN A cross-sectional health survey. SETTING All residential census tracts in Genesee County, Michigan, USA. PARTICIPANTS 498 adults who reported having children in their households, extracted from 2,932 randomly selected adult participants in the 2009 and 2011 surveys. MAIN MEASURES Stepwise logistic regression was used to predict two dependent variables: children's lack of any visits to dentists' offices and unmet dental care needs (defined as needing dental care but not receiving it due to cost) in the previous year as reported by the adults. Independent variables included gender, age, education, race/ethnicity, financial planning, financial distress, fear of crime, stress, depressive symptoms, experiences of discrimination, and neighbourhood social capital. RESULTS Of the 498 adults, 29.9% reported that they had children who had not visited a dentist in the past 12 months and 13% reported that they had household children with unmet dental care needs in the past year. Adults who reported higher depressive symptoms, lower neighbourhood social capital, greater financial distress, and who were younger were more likely to have household children who did not visit a dentist in the past year. Financial distress was the only significant predictor when controlling for other variables to predict unmet dental care needs. CONCLUSIONS Factors beyond financial distress affect children's dental care; these include parental depressive symptoms and lower neighbourhood social capital. Interventions promoting parental mental health and social integration may increase dental care among children.
Collapse
|
7
|
Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 2013; 27:1707-14. [PMID: 23364621 PMCID: PMC3740399 DOI: 10.1038/leu.2013.29] [Citation(s) in RCA: 123] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2012] [Revised: 01/15/2013] [Accepted: 01/21/2013] [Indexed: 11/09/2022]
Abstract
This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and varying degrees of renal impairment, including patients on chronic hemodialysis. Patients were grouped by creatinine clearance: >80 ml/min, 50-80 ml/min, 30-49 ml/min, <30 ml/min and chronic hemodialysis. Carfilzomib was administered on days 1, 2, 8, 9, 15 and 16 in 28-day cycles: 15 mg/m(2) (Cycle 1), 20 mg/m(2) (Cycle 2) and 27 mg/m(2) (Cycles 3+). There were no differences in carfilzomib clearance or exposure among patients with normal renal function and any group with renal impairment. Grade 3/4 adverse events (AEs) included anemia (28.0%), thrombocytopenia (20.0%), lymphopenia (18.0%) and fatigue (14.0%). AEs were similar among groups. At 15 mg/m(2), proteasome inhibition up to 85% was observed and did not differ among groups. Although nearly 50% of patients were refractory to both bortezomib and lenalidomide, end of study partial response or better (overall response rate) was 25.5% with 7.9 months median duration of response. In conclusion, the pharmacokinetics and safety of carfilzomib were not influenced by the degree of baseline renal impairment, including in patients on dialysis, and carfilzomib was well tolerated and demonstrated promising efficacy.
Collapse
Affiliation(s)
- A Z Badros
- M and S Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Shelton G, Vieira N, Guo L, Bennett R, Kunkel L, Zatz M. O.2 Dystrophin-deficient muscular dystrophy in a pedigree of Labrador retrievers without obvious clinical manifestations. Neuromuscul Disord 2011. [DOI: 10.1016/j.nmd.2011.06.758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
9
|
Burd A, Kunkel L, Fattaey A. 137 Preclinical characterization of ACTB-1010, an orally activity Aurora kinase inhibitor. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71842-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
10
|
Burd A, Whiteside M, Castillo J, Kunkel L, Fattaey A. 141 ACTB-1003 - a unique oral pan FGFR and PI3K pathway inhibitor with divergent modes of activity. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71846-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
11
|
Ordentlich P, Lee G, Kunkel L, Sausville E. Abstract B196: Entinostat: A novel class 1 isoform selective histone deacetylase inhibitor (HDACi) with unique pharmacological properties. Mol Cancer Ther 2009. [DOI: 10.1158/1535-7163.targ-09-b196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Several distinct HDACi have been characterized. While we do not fully understand how structure and selectivity correlate with efficacy and toxicity, targeting selective isoforms involved in maintaining tumor proliferation may be sufficient for antitumor activity. Entinostat (ENT) is a benzamide Class I selective compound and has low nM MEC50 values against HDAC1, and low µM to HDAC 2 , 3 and 9, with no inhibition of Class II HDAC 4,6,7 and 8 (Khan 2008). In contrast, the hydroxamate, vorinostat (VOR) has µM inhibition of Class II HDACs. HDACi kinetic properties also influence activity of both histones and other proteins involved in diverse biologic processes. VOR has a fast-on/fast-off rate to HDAC 1 and 3. In contrast, ENT has a slow tight binding that translates into sustained inhibition of HDAC enabling prolonged activation (or repression) of genes even after elimination of the inhibitor.
To better understand differences and similarities of PK/PD profiles of ENT and VOR data from the Ph 1 studies were reviewed. In the NCI Ph 1 study (Ryan 2005, Kummar 2007) 71 patients (68 solid tumors) were treated either daily (n=2) every 2 weeks (wks) (n=28) or weekly for 4 wks with 2 wks off (n=41). Ph 1 data for VOR has been previously summarized (Kelly 2005).
ENT displayed both intra-and inter-patient variability as seen with most oral cancer agents. Daily dosing was not tolerated and PK data suggested that ENT had a 30–50x longer t1/2 than predicted from animal models. Subsequently doses were tested every 2 wks or weekly and up to 10 mg/m2 were tolerated. ENT absorption was variable with a median Tmax of 2 hours (range 0.5 to 60 hrs), the elimination is bi-exponential and the terminal halflife was 30 to 80 hours (hrs). ENT is detectable within 8 hrs and remains above baseline throughout the treatment cycle even after 5 days (Gojo 2007). In contrast VOR has a t1/2 ranging from 91–127 minutes. The AUC with both agents appears to have a linear increase with dose. PK parameters have led to once wkly or every 2 wk dosing with ENT and qD dosing with VOR. Pharmacodynamic analysis on histone acetylation in peripheral blood mononuclear cells is evident at 8-12 hs with ENT and 4–10 with VOR, and acetylation increases with time and continued treatment with both agents, however is not dose related with ENT. Acetylation persists for at least 2 to 3 wks following the last ENT administration in contrast to 10 hrs with VOR. Antitumor activity in Ph 1 was demonstrated with both agents; with SD (for > 90 days) in 30–40% of patients with multiple tumor types. PRs were seen with ENT in melanoma and sarcoma, and mesothelioma and thyroid cancer with VOR. Responses were not dose related. The most common toxicities with both drugs are primarily gastrointestinal, asthenia, and electrolyte abnormalities. Grade 3/4 cytopenias occur in 10–16% of solid tumor patients with both agents and is dose dependent with ENT. With every 2 wks or weekly dosing continuous target inhibition (up to 3 wks without interruption) can be achieved with ENT. Normal cells appear to be relatively resistant to prolonged exposure and therapy is well tolerated. Potent Class I HDACi (and/or related proteins) targeted by ENT is sufficient to induce antitumor activity in a broad spectrum of tumors. Structural differences, prolonged PD effects and impact on other cellular processes may provide important antitumor activity with ENT not achieved with other HDACi.
Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B196.
Collapse
Affiliation(s)
| | | | | | - Edward Sausville
- 3 University of Maryland Greenebaum Cancer Center, Baltimore, MD
| |
Collapse
|
12
|
Jagannath S, Vij R, Stewart K, Somlo G, Jakubowiak A, Trudel S, Schwartz R, Siegel D, Kunkel L. Final results of PX-171–003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8504] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8504 Background: CFZ is a novel proteasome inhibitor of the epoxyketone class that exhibits a high level of proteasome selectivityand demonstrates antitumor activity in bortezomib (BTZ)-resistant MM pts in phase I studies. Methods: PX-171–003-A0 was an open-label, multicenter study that enrolled MM pts who relapsed from >2 prior therapies, failed BTZ and at least 1 immunomodulatory agent [thalidomide (THAL) or lenalidomide (LEN)], and were refractory to last treatment [progressing on or within 60 d of last therapy or <25% response to last therapy]. Pts received CFZ 20 mg/m2 IV d 1, 2, 8, 9, 15 and 16 every 28 d for up to 12 cycles (C). Clinical benefit response (CBR) was defined as MR or better. Results: 46 pts were enrolled, including 78% with progression on or within 60 d of last therapy and 22% with no response to last therapy. 39 pts completed at least 1 C of CFZ, had measurable M-protein, and were evaluable for response. Median prior therapies was 5 (range 2–15). 100% of pts received prior BTZ, 91% prior THAL, 89% prior LEN, and 83% prior stem cell transplant (SCT) and all had failed combinations including anthracyclines (80%) and/or alkylating agents (94%). Pts received a median of 3 C (range 1–12); 13 pts completed ≥6 C. CBR was 26% (10/39 eval pts), including 5 pts achieving PR and 5 pts achieving MR. 5 BTZ-refractory pts achieved MR or PR. Median TTP was 6.2 mo, the median DOR for the MR + PR was 7.4 mo. 8/10 pts achieved response during C1. 16 additional pts achieved SD for at least 6 wks. The most common adverse events were fatigue, anemia, thrombocytopenia, nausea, upper respiratory infection, increased creatinine and diarrhea. Peripheral neuropathy occured in < 10% of pts with 1 Gr 3 in a pt with pre-existing Gr 2. Conclusions: Single-agent CFZ achieved a TTP of > 6 mo in relapsed and refractory MM pts who failed available therapies. 26% of patients had at least an MR and median duration of >7 mo with this steroid- and anthracycline-sparing regimen. CFZ toxicities were manageable and importantly, exacerbation of pre-existing PN was rare. The study has been expanded to enroll an additional 250 pts in this unmet medical need population at an escalated dose, and treatment has been extended beyond a year. [Table: see text]
Collapse
Affiliation(s)
- S. Jagannath
- St. Vincent's Comprehensive Cancer Center, New York, NY; Washington University School of Medicine, St. Louis, MO; Mayo Clinic, Scottsdale, AZ; City of Hope, Duarte, CA; University of Michigan, Ann Arbor, MI; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - R. Vij
- St. Vincent's Comprehensive Cancer Center, New York, NY; Washington University School of Medicine, St. Louis, MO; Mayo Clinic, Scottsdale, AZ; City of Hope, Duarte, CA; University of Michigan, Ann Arbor, MI; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - K. Stewart
- St. Vincent's Comprehensive Cancer Center, New York, NY; Washington University School of Medicine, St. Louis, MO; Mayo Clinic, Scottsdale, AZ; City of Hope, Duarte, CA; University of Michigan, Ann Arbor, MI; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - G. Somlo
- St. Vincent's Comprehensive Cancer Center, New York, NY; Washington University School of Medicine, St. Louis, MO; Mayo Clinic, Scottsdale, AZ; City of Hope, Duarte, CA; University of Michigan, Ann Arbor, MI; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - A. Jakubowiak
- St. Vincent's Comprehensive Cancer Center, New York, NY; Washington University School of Medicine, St. Louis, MO; Mayo Clinic, Scottsdale, AZ; City of Hope, Duarte, CA; University of Michigan, Ann Arbor, MI; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - S. Trudel
- St. Vincent's Comprehensive Cancer Center, New York, NY; Washington University School of Medicine, St. Louis, MO; Mayo Clinic, Scottsdale, AZ; City of Hope, Duarte, CA; University of Michigan, Ann Arbor, MI; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - R. Schwartz
- St. Vincent's Comprehensive Cancer Center, New York, NY; Washington University School of Medicine, St. Louis, MO; Mayo Clinic, Scottsdale, AZ; City of Hope, Duarte, CA; University of Michigan, Ann Arbor, MI; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - D. Siegel
- St. Vincent's Comprehensive Cancer Center, New York, NY; Washington University School of Medicine, St. Louis, MO; Mayo Clinic, Scottsdale, AZ; City of Hope, Duarte, CA; University of Michigan, Ann Arbor, MI; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - L. Kunkel
- St. Vincent's Comprehensive Cancer Center, New York, NY; Washington University School of Medicine, St. Louis, MO; Mayo Clinic, Scottsdale, AZ; City of Hope, Duarte, CA; University of Michigan, Ann Arbor, MI; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| |
Collapse
|
13
|
Niesvizky R, Bensinger W, Vallone M, Gutierrez A, Kunkel L. PX-171–006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): Preliminary results. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8541] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8541 Background: CFZ is a highly specific proteasome inhibitor with single agent activity in relapsed/refractory MM (ASH 2008). The purpose of this study is to evaluate the safety and activity of CFZ in combination with LEN and loDex. Methods: This phase Ib trial evaluates 4 dose levels (≥ 3 pts each) to define the maximum tolerated dose (MTD) of CFZ/LEN/loDex in relapsed/refractory MM pts who failed 1–3 prior therapies, including prior LEN or bortezomib (BTZ). CFZ IV 15- 20 mg/m2 (d1,2,8,9,15,16), LEN 10–20 mg po (d1–21) and loDex 40 mg po (d1, 8, 15, 22) in 28-day cycles (C). An additional 10–15 pts will be evaluated at the highest dose level reached. Dose limiting toxicity (DLT) has been defined as grade (G) ≥ 3 non- hematologic; G4 neutropenia for > 7d and/or neutropenic fever; G4 thrombocytopenia > 7d or G3-G4 thrombocytopenia in association with bleeding. Overall response (CR/sCR, VGPR/PR) is assessed by IWG criteria, with secondary assessment by modified EBMT criteria which includes MR. Results: 11 pts have been enrolled. 8/11 are evaluable for response and toxicity. Median prior lines of therapy was 2 (range 2–3). Prior therapies included DEX (8/8), BTZ (6/8), LEN (7/8), alkylators (6/8), anthracyclines (5/8), stem cell transplant (5/8), and thalidomide (1/8); 6/8 pts had received both LEN and BTZ. MTD has not yet been reached after the first 2 dose cohorts. No drug related SAEs or G3/4 treatment emergent AEs were reported. Responses to date with a median of 2 C (range 1–4) are shown below. Responses were rapid and occurred within the first 28-day cycle. Conclusions: CFZ/LEN/loDex in combination was well tolerated in the first 2 cohorts. There have been no myleosuppressive or renal DLTs. The combination has achieved early encouraging responses in pts who had failed both LEN and BTZ at doses well below the single agent MTD of either LEN or CFZ. Dose escalation is ongoing. Updated data will be presented at the meeting. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- R. Niesvizky
- Weill Cornell Medical College, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Proteolix, Inc, South San Francisco, CA
| | - W. Bensinger
- Weill Cornell Medical College, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Proteolix, Inc, South San Francisco, CA
| | - M. Vallone
- Weill Cornell Medical College, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Proteolix, Inc, South San Francisco, CA
| | - A. Gutierrez
- Weill Cornell Medical College, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Proteolix, Inc, South San Francisco, CA
| | - L. Kunkel
- Weill Cornell Medical College, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Proteolix, Inc, South San Francisco, CA
| |
Collapse
|
14
|
Rosen PJ, Gordon M, Lee PN, Sausville E, Papadopoulos KP, Wong AF, Vallone M, Kunkel L, Infante J, Burris HA. Phase II results of Study PX-171–007: A phase Ib/II study of carfilzomib (CFZ), a selective proteasome inhibitor, in patients with selected advanced metastatic solid tumors. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3515] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3515 Background: CFZ is a novel proteasome inhibitor of the peptide epoxyketone class that exhibits a high level of selectivity for proteasome active sites. This phase 1/2 study assessed the maximum tolerated dose (MTD), safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of CFZ in patients (pts) with advanced metastatic solid tumors. Methods: Pts failing ≥ 2 prior treatments were enrolled in the phase 1 3+3 dose escalation study. Pts received CFZ IV Day (D) 1, 2, 8, 9, 15 and 16 every 28 d for up to 12 cycles (C) Cycle 1 D1, D2 dosing in all cohorts was at 20 mg/m2. Subsequent doses remained at 20 mg/m2 or were escalated to 27 or 36 mg/m2 in a stepped up regimen on D8. At 20/36 mg/m2, 1 pt had a DLT (Grade 3 fatigue) and established the phase 2 dose. Phase 2 is designed as a Simon 2 stage of 70 pts split into 5 subgroups (small cell lung [SCLC], non-small cell lung [NSCLC], ovarian, renal, and other cancer). Tumor response was measured every 2 C. ORR, defined as CR+PR+SD, to 16 wks of CFZ. Stage 2 will open if a 1 PR or better at 16 wks occurs in a selected subgroup. Results: 14 pts in phase 1 and 51 pts in phase 2 (23M/28F, mean age 61 yrs) received a total of 154.5 cycles of CFZ. Median cycles administered was 1.7 (range 1 to 12). To date, there were 6 SCLC, 10 NSCLC, 11 ovarian, 6 renal, and 18 other cancer patients enrolled to the Simon stage 1. Efficacy of SD or better is detailed in the table. The most common AEs included fatigue headache, diarrhea, nausea and constipation. Notable was the absence of grade > 1 peripheral neuropathy and severe hematologic toxicities. Final results of the PK and PD will be reported. Conclusions: CFZ is active as a single agent in relapsed solid tumors demonstrating PR in both renal and SCLC; and SD >16 wks in mesothelioma, ovarian, renal and NSCLC. The 20/36 mg/m2 QDx2 dose schedule was well tolerated and lacks severe myelosuppression, hepatotoxicity and neuropathy which make CFZ an attractive agent to combine with traditional or novel targeted agents. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- P. J. Rosen
- Tower Cancer Research Foundation, Beverly Hills, CA; Premiere Oncology, Scottsdale, AZ; University of Maryland Medical Center, Baltimore, MD; South Texas Oncology and Hematology, San Antonio, TX; Proteolix, South San Francisco, CA; Sarah Cannon Cancer Center, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| | - M. Gordon
- Tower Cancer Research Foundation, Beverly Hills, CA; Premiere Oncology, Scottsdale, AZ; University of Maryland Medical Center, Baltimore, MD; South Texas Oncology and Hematology, San Antonio, TX; Proteolix, South San Francisco, CA; Sarah Cannon Cancer Center, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| | - P. N. Lee
- Tower Cancer Research Foundation, Beverly Hills, CA; Premiere Oncology, Scottsdale, AZ; University of Maryland Medical Center, Baltimore, MD; South Texas Oncology and Hematology, San Antonio, TX; Proteolix, South San Francisco, CA; Sarah Cannon Cancer Center, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| | - E. Sausville
- Tower Cancer Research Foundation, Beverly Hills, CA; Premiere Oncology, Scottsdale, AZ; University of Maryland Medical Center, Baltimore, MD; South Texas Oncology and Hematology, San Antonio, TX; Proteolix, South San Francisco, CA; Sarah Cannon Cancer Center, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| | - K. P. Papadopoulos
- Tower Cancer Research Foundation, Beverly Hills, CA; Premiere Oncology, Scottsdale, AZ; University of Maryland Medical Center, Baltimore, MD; South Texas Oncology and Hematology, San Antonio, TX; Proteolix, South San Francisco, CA; Sarah Cannon Cancer Center, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| | - A. F. Wong
- Tower Cancer Research Foundation, Beverly Hills, CA; Premiere Oncology, Scottsdale, AZ; University of Maryland Medical Center, Baltimore, MD; South Texas Oncology and Hematology, San Antonio, TX; Proteolix, South San Francisco, CA; Sarah Cannon Cancer Center, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| | - M. Vallone
- Tower Cancer Research Foundation, Beverly Hills, CA; Premiere Oncology, Scottsdale, AZ; University of Maryland Medical Center, Baltimore, MD; South Texas Oncology and Hematology, San Antonio, TX; Proteolix, South San Francisco, CA; Sarah Cannon Cancer Center, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| | - L. Kunkel
- Tower Cancer Research Foundation, Beverly Hills, CA; Premiere Oncology, Scottsdale, AZ; University of Maryland Medical Center, Baltimore, MD; South Texas Oncology and Hematology, San Antonio, TX; Proteolix, South San Francisco, CA; Sarah Cannon Cancer Center, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| | - J. Infante
- Tower Cancer Research Foundation, Beverly Hills, CA; Premiere Oncology, Scottsdale, AZ; University of Maryland Medical Center, Baltimore, MD; South Texas Oncology and Hematology, San Antonio, TX; Proteolix, South San Francisco, CA; Sarah Cannon Cancer Center, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| | - H. A. Burris
- Tower Cancer Research Foundation, Beverly Hills, CA; Premiere Oncology, Scottsdale, AZ; University of Maryland Medical Center, Baltimore, MD; South Texas Oncology and Hematology, San Antonio, TX; Proteolix, South San Francisco, CA; Sarah Cannon Cancer Center, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN
| |
Collapse
|
15
|
Vij R, Wang M, Orlowski R, Stewart AK, Jagannath S, Kukreti V, Le MH, Kunkel L, Siegel D. PX-171–004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8537] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8537 Background: Carfilzomib (CFZ) is a proteasome inhibitor, active against hematologic malignancies. Preclinically, CFZ overcomes bortezomib (BTZ) resistance in multiple tumors, including myeloma (MM). PX-171–004 is an ongoing Phase II study evaluating safety and efficacy of CFZ in MM patients with relapsed disease after 1–3 prior therapies. Overall Response Rate (ORR) of 35.5% for all subjects was previously reported (ASH 2008); updated data are now available. Methods: Patients were divided into two cohorts: BTZ-naïve and BTZ-exposed. CFZ 20 mg/m2 was administered Days 1, 2, 8, 9, 15 and 16 in a 28-day cycle, for up to 12 cycles. Dexamethasone 4 mg po was administered prior to each dose in Cycle 1. The primary endpoint was ORR, defined as Partial Response (PR) or better. Secondary endpoints included Duration Of Response (DOR) and Time To Progression (TTP). Results: 31 patients were enrolled; 14 (45%) BTZ-naïve and 17 (55%) BTZ-exposed. Of the BTZ-exposed cohort, 2 subjects received BTZ exclusively as a single agent, 6 had BTZ in a chemotherapy combination, and 9 received BTZ in a transplant regime. Overall, 23 (74%) subjects had > 1 prior therapy and 27 (87%) received transplant. In BTZ-naïve patients, CFZ achieved an ORR of 57%; median DOR of 8.6 mos (range >1.9 to >9.7 mos). To date, 7 patients (50%) remain progression free and 3 patients have completed 12 cycles. The median follow-up was 10 mos and the median TTP has not been reached. For the BTZ- exposed group, CFZ achieved an ORR of 18%; median DOR not yet reached (>8.5 mos) (range >1 d to >8.5 mos). 7 patients (41%) are progression free and 3 patients have completed 12 cycles. Median follow-up and TTP were 9.2 and 8.9 mos, respectively. Conclusions: These preliminary results demonstrate that single-agent CFZ is tolerable for at least 1 yr and achieves sustained responses in relapsed MM. Prior BTZ mono/combination therapy does not preclude durable response with CFZ. These data support continuing evaluation of CFZ in the treatment of relapsed MM. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- R. Vij
- Washington University School of Medicine, St Louis, MO; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mayo Clinic, Scottsdale, AZ; St. Vincent's Comprehensive Cancer Center, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - M. Wang
- Washington University School of Medicine, St Louis, MO; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mayo Clinic, Scottsdale, AZ; St. Vincent's Comprehensive Cancer Center, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - R. Orlowski
- Washington University School of Medicine, St Louis, MO; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mayo Clinic, Scottsdale, AZ; St. Vincent's Comprehensive Cancer Center, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - A. K. Stewart
- Washington University School of Medicine, St Louis, MO; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mayo Clinic, Scottsdale, AZ; St. Vincent's Comprehensive Cancer Center, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - S. Jagannath
- Washington University School of Medicine, St Louis, MO; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mayo Clinic, Scottsdale, AZ; St. Vincent's Comprehensive Cancer Center, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - V. Kukreti
- Washington University School of Medicine, St Louis, MO; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mayo Clinic, Scottsdale, AZ; St. Vincent's Comprehensive Cancer Center, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - M. H. Le
- Washington University School of Medicine, St Louis, MO; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mayo Clinic, Scottsdale, AZ; St. Vincent's Comprehensive Cancer Center, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - L. Kunkel
- Washington University School of Medicine, St Louis, MO; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mayo Clinic, Scottsdale, AZ; St. Vincent's Comprehensive Cancer Center, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| | - D. Siegel
- Washington University School of Medicine, St Louis, MO; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mayo Clinic, Scottsdale, AZ; St. Vincent's Comprehensive Cancer Center, New York, NY; Princess Margaret Hospital, Toronto, ON, Canada; Proteolix, Inc., South San Francisco, CA; Hackensack University Medical Center, Hackensack, NJ
| |
Collapse
|
16
|
Jagannath S, Vij R, Stewart AK, Somlo G, Jakubowiak A, Reiman T, Trudel S, Taylor J, Fuhrman D, Cruickshank S, Schwartz R, Kunkel L, Siegel D. A377 Phase II Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003). ACTA ACUST UNITED AC 2009. [DOI: 10.1016/s1557-9190(11)70562-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Lewis N, Rosen LS, Rocha Lima C, Marshall JL, Jones SF, Cohen RB, Kunkel L, Stewart S, Burris HA. Phase I experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.3023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Baz R, Fanning S, Kunkel L, Gaballa S, Karam MA, Reed J, Kelly M, Hussein M. Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma. Leuk Lymphoma 2008; 48:2338-44. [PMID: 18067008 DOI: 10.1080/10428190701644330] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Clonotypic B lymphocytes may underlie relapse of patients with multiple myeloma. Rituximab, a CD20 monoclonal antibody, may result in eradication of the monoclonal B cells. We conducted a phase II study of rituximab in combination with melphalan and prednisone therapy (MP) followed by rituximab maintenance in newly diagnosed multiple myeloma patients. Sixteen patients (35%) had CD20 positive bone marrow plasma cells, while 9 patients (20%) had unknown CD20 status. No patient had a complete remission, 26 patients (58%) had a partial response, 6 patients (13%) had a minimal response, and 8 patients (18%) had stable disease. The median event-free survival was 14 months, and the 7-year overall survival was 30%. The toxicity of the combination was overall manageable and consistent with what is generally noted with MP chemotherapy. The combination of rituximab to MP therapy did not result in improved response rate or event-free survival.
Collapse
Affiliation(s)
- Rachid Baz
- Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Vafa O, Kharki S, Vielmetter J, Chamberlain A, Hammond P, Dang W, Carmichael D, Kunkel L, Barbosa M, Desjarlais J. Anti-EpCAM XmAb antibodies with improved cytotoxicity. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.12506] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
12506 Background: The epithelial cell adhesion molecule (EpCAM), also known as epithelial protein 2 (EGP-2) or 17–1A antigen, is a trans-membrane protein expressed on the surfaces of most carcinomas, including those of pancreatic, colorectal, prostate, breast, kidney, lung, and ovarian origins. Moderate affinity antibodies (Abs) such as 17–1A (Kd ∼ 10−7 nM) have been safe in humans albeit with limited clinical efficacy. Attempts to improve clinical efficacy by enhancing antigen affinity (Kd ∼ 10−9 nM) have led to serious clinical toxicity, including pancreatitis. These observations raise the question of whether a moderate affinity Ab with enhanced effector function will be both safe and clinically efficacious. Methods: We applied our proprietary XmAb™ technologies to humanize the 17–1A variable domain and engineer a human IgG1 Fc domain to increase affinity for the activating receptor FcγRIIIa. Ab binding to Ep-CAM or to Fc receptors was tested with Biacore and/or AlphaScreen binding assays. In vitro cytotoxic activity against representative cancer cell lines was measured with Antibody Dependent Cell-mediated Cytotoxicity (ADCC) assays, using human PBMC as effector cells. Results: Humanized anti-EpCAM Abs have affinity for EpCAM similar to the parent 17–1A. Affinity for the activating FcγRIIIa was increased 100-fold relative to a control Ab with an IgG1 Fc domain. As expected, these Abs exhibit dramatically enhanced ADCC against multiple cancer cell lines relative to 17–1A and IgG1 control Abs. Despite their moderate affinity for EpCAM, these novel Abs have in vitro cytotoxicity comparable to the high affinity Ab ING-1. CDC activities of these Abs were similar to chimeric 17–1A. Conclusions: We have demonstrated that antibodies with moderate affinity for EpCAM and increased FcγRIIIa affinity exhibit superior cancer cell killing via an ADCC mechanism. The humanized nature and the increased cytotoxicity of anti-EpCAM XmAb™ antibodies make them promising candidates for clinical development of a novel pan-carcinoma Ab that is superior to 17–1A. [Table: see text]
Collapse
|
20
|
Henderson DC, Kunkel L, Nguyen DD, Borba CP, Daley TB, Louie PM, Freudenreich O, Cather C, Evins AE, Goff DC. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006; 113:142-7. [PMID: 16423166 DOI: 10.1111/j.1600-0447.2005.00612.x] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE We conducted this 6-week open-label trial to examine the effects of adjunctive aripiprazole in clozapine-treated subjects on weight, lipid and glucose metabolism, as well as positive and negative symptoms of schizophrenia. METHOD Ten clozapine-treated subjects received aripiprazole augmentation; eight completed the 6-week trial and two ended at week 4. Eighty percent were male, the mean age was 38.7 +/- 8.9 years and the mean clozapine dose was 455 +/- 83 mg daily. RESULTS There was a significant decrease in weight (P = 0.003), body mass index (P = 0.004), fasting total serum cholesterol (P = 0.002) and total triglycerides (P = 0.04) comparing baseline to study endpoint. There was no significant change in total Positive and Negative Syndrome Scale scores. CONCLUSION This combination may be useful for clozapine-associated medical morbidity and must be studied in placebo-controlled double-blind randomized trials to determine efficacy and safety.
Collapse
Affiliation(s)
- D C Henderson
- Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Hibbard JH, Greenlick M, Jimison H, Capizzi J, Kunkel L. The impact of a community-wide self-care information project on self-care and medical care utilization. Eval Health Prof 2001; 24:404-23. [PMID: 11817199 DOI: 10.1177/01632780122034984] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
This study assesses the effects of the Healthwise Communities Project (HCP) on use of self-care resources and health care utilization. The intervention included the distribution of the Healthwise Handbook, the provision of a telephone advice line, and a Web site. All of these products use a symptom-based approach and are aimed at a general population. A quasi-experimental design was used with two comparison communities. Measurements over time assessed the effects of the HCP while controlling for secular trends. Survey and utilization data are used to assess the effect of the intervention. Findings indicate that the community intervention increased the use of self-care resources. Users believe that these products help them make better decisions regarding when to seek care and how to self-treat problems. Most believe that using the self-care resources saved them from seeking unnecessary care. The findings from the utilization data provide some evidence to support this conclusion.
Collapse
|
22
|
Wagner TH, Hibbard JH, Greenlick MR, Kunkel L. Does providing consumer health information affect self-reported medical utilization? Evidence from the Healthwise Communities Project. Med Care 2001; 39:836-47. [PMID: 11468502 DOI: 10.1097/00005650-200108000-00009] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To determine whether providing health information to residents of Boise ID had an effect on their self-reported medical utilization. RESEARCH DESIGN The Healthwise Communities Project (HCP) evaluation followed a quasi-experimental design. SUBJECTS Random households in metropolitan zip codes were mailed questionnaires before and after the HCP. A total of 5,909 surveys were returned. MEASURES The dependent variable was self-reported number of visits to the doctor in the past year. A difference-in-differences estimator was used to assess the intervention's community-level effect. We also assessed the intervention's effect on the variance of self-report utilization. RESULTS Boise residents had a higher adjusted odds of entering care (OR = 1.27, 95% CI 0.88, 1.85) and 0.1 more doctor visits compared with residents in the control cities; however, for both outcomes, the effects were small and not significant. Although the means changed little, the data suggest that the variance of utilization in Boise decreased. CONCLUSIONS The HCP had a small effect on overall self-reported utilization. Although the findings were not statistically significant, a posthoc power analysis revealed that the study was underpowered to detect effects of this magnitude. It may be possible to achieve larger effects by enrolling motivated people into a clinical trial. However, these data suggest that population-based efforts to provide health information have a small effect on self-reported utilization.
Collapse
Affiliation(s)
- T H Wagner
- VA HSR&D Health Economics Resource Center, Center for Primary Care and Outcomes Research, and Center for Health Policy, Stanford University, CA, USA.
| | | | | | | |
Collapse
|
23
|
Schiller G, Wong S, Lowe T, Snead G, Paquette R, Sawyers C, Wolin M, Kunkel L, Ting L, Li G, Territo M. Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission. Leukemia 2001; 15:757-63. [PMID: 11368436 DOI: 10.1038/sj.leu.2402113] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In order to improve leukemia-free survival we evaluated the feasibility and efficacy of autologous transplantation of interleukin-2 (IL-2)-mobilized peripheral blood progenitor cells for adult patients with acute myelogenous leukemia in first remission. Forty-nine consecutive patients (median age 49, range 21-70) with acute myelogenous leukemia in first remission were enrolled on a study of high-dose cytarabine/mitoxantrone consolidation chemotherapy with post-recovery IL-2 used as a method of in vivo purging for the purpose of autologous peripheral blood progenitor cell transplantation. A median of 2.08 x 10(6) CD34+ peripheral blood progenitor cells/kg were infused 1 day after preparative conditioning with 11.25 Gy total body irradiation and cyclophosphamide (120 mg/kg). Forty-one patients received myeloablative chemoradiotherapy followed by the infusion of IL-2-mobilized autologous peripheral blood progenitor cells. The median times to both neutrophil and platelet recovery were 16 days (range, 2-43) and 23 days (8-318+ days), respectively. Twenty-seven patients remain alive with 24 in continued first complete remission. Median remission duration for all eligible patients is 8 months, and actuarial leukemia-free survival is 49+/-15%. The actuarial risk of relapse is 43+/-16%. Toxicity of autologous peripheral blood progenitor cell transplant included treatment-related death in three patients and serious organ toxicity in 12. Advanced age was a negative prognostic factor for leukemia-free survival. Results were compared to an age-matched historical control treated with autologous transplantation of chemotherapy-mobilized progenitor cells; no significant difference in favor of IL-2 mobilization could be demonstrated. Our results demonstrate that autologous transplantation of IL-2-mobilized peripheral blood progenitor cells is feasible in an unselected population of adult patients with acute myelogenous leukemia in first remission with minimal toxicity but no clear evidence of benefit in leukemia-free survival.
Collapse
Affiliation(s)
- G Schiller
- Department of Medicine, UCLA School of Medicine, Los Angeles, CA 90095, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Esses D, Gallagher EJ, Iannaccone R, Bijur P, Srinivas VS, Rose H, Kunkel L, Sokolof J. Six-hour versus 12-hour protocols for AMI: CK-MB in conjunction with myoglobin. Am J Emerg Med 2001; 19:182-6. [PMID: 11326340 DOI: 10.1053/ajem.2001.21719] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
The objective was to test the hypothesis that a protocol using myoglobin and creatine kinase-MB (CK-MB) can rapidly and safely exclude myocardial infarction (MI). The study used a prospective, convenience cohort of ED patients with clinically suspected myocardial ischemia. Myoglobin was measured on presentation, 2 and 6 hours later; CK-MB was measured on presentation, 6, 12, and 18 hours later. Of 519 patients, 76 (15%) had MIs, all of whom "ruled in" within 12 hours using a combination of myoglobin and CK-MB, for a sensitivity of 100% (95% CI, 95% to 100%), specificity of 92% (95% CI, 89% to 94%), LR (+) of 12 (95% CI, 9 to 16), and an LR (-) of 0.03 (95% CI, 0.0 to 0.05). Of the 76 patients with MIs, 73 ruled in with a 6 hour protocol, also using a combination of CK-MB and myoglobin, for a sensitivity of 96% (95% CI, 89% to 99%), specificity of 92% (95% CI, 89% to 94%), LR (+) of 11 (95% CI, 8 to 16), and an LR (-) of 0.04 (95% CI, 0.01 to 0.12). Our results support the hypothesis that, using an abbreviated protocol with CK-MB and myoglobin, MI can be reliably ruled out in ED patients with suspected ischemia.
Collapse
Affiliation(s)
- D Esses
- Department of Emergency Medicine, Montefiore Medical Center, Teaching Hospital of the Albert Einstein College of Medicine, 111 East 210th Street, Bronx, NY 10467, USA.
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19:2153-64. [PMID: 11304767 DOI: 10.1200/jco.2001.19.8.2153] [Citation(s) in RCA: 414] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Rituximab has been reported to have little activity in small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) and to be associated with significant infusion-related toxicity. This study sought to decrease the initial toxicity and optimize the pharmacokinetics with an alternative treatment schedule. PATIENTS AND METHODS Thirty three patients with SLL/CLL received dose 1 of rituximab (100 mg) over 4 hours. In cohort I (n = 3; 250 mg/m(2)) and cohort II (n = 7; 375 mg/m(2)) rituximab was administered on day 3 and thereafter three times weekly for 4 weeks using a standard administration schedule. Cohort III (n = 23; 375 mg/m(2)) administered rituximab similar to cohort II for the first two treatments and then over 1 hour thereafter. RESULTS A total of 33 CLL/SLL patients were enrolled; only one patient discontinued therapy because of infusion-related toxicity. Thirteen patients developed transient hypoxemia, hypotension, or dyspnea that were associated with significant changes in baseline interleukin-6, interleukin-8, tumor necrosis factor alpha, and interferon gamma compared with those not experiencing such reactions. Infusion-related toxicity occurred more commonly in older (median age 73 v 62 years; P =.02) patients with no other pretreatment clinical or laboratory features predicting occurrence of these events. The overall response rate was 45% (3% CR, 42% PR; 95% CI 28% to 64%). Median response duration for these 15 patients was 10 months (95% CI, 6.8-13.2; range, 3 to 17+). CONCLUSION Rituximab administered thrice weekly for 4 weeks demonstrates clinical efficacy and acceptable toxicity. Initial infusion-related events seem to be cytokine mediated and resolve by the third infusion making rapid administration possible. Future combination studies of rituximab with other therapies in CLL seem warranted.
Collapse
MESH Headings
- Aged
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/adverse effects
- Antibodies, Monoclonal/pharmacology
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/adverse effects
- Antineoplastic Agents/pharmacology
- Cytokines/pharmacology
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Dyspnea/chemically induced
- Female
- Humans
- Hypotension/chemically induced
- Hypoxia/chemically induced
- Infusions, Intravenous
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Male
- Middle Aged
- Rituximab
- Treatment Outcome
Collapse
Affiliation(s)
- J C Byrd
- Division of Hematology-Oncology, Department of Medicine and the Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Kunkel L, Wong A, Maneatis T, Nickas J, Brown T, Grillo-López A, Benyunes M, Grobman B, Dillman RO. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update. Semin Oncol 2000; 27:53-61. [PMID: 11226001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
Rituximab (Rituxan; Genentech, Inc, South San Francisco, CA and IDEC Pharmaceutical Corporation, San Diego, CA), the first monoclonal antibody approved in the United States for the treatment of cancer, is indicated for the treatment of patients with relapsed or refractory CD20+ low-grade non-Hodgkin's lymphoma. From November 1997 through May 1999, approximately 36,000 patients have been treated with rituximab. Serious cardiopulmonary infusion reactions culminating in death have been reported to occur in approximately 0.04% to 0.07% of patients. Post-approval tumor lysis syndrome has been reported within 12 to 24 hours after the first antibody infusion and is estimated to occur in 0.04% to 0.05% of patients. The risk of tumor lysis appears to be higher in patients with high numbers of circulating malignant cells. Serious infusion-related adverse drug reactions, most often consisting of cardiopulmonary reactions associated with the rapid lysis of large numbers of circulating malignant cells, have been fatal in approximately 0.5 per 1,000 treated patients. Major risk factors include high numbers of circulating malignant lymphoma cells, pulmonary infiltrates or lymphoma involvement, and prior cardiovascular disease. This report updates the safety experience of rituximab therapy with data from clinical trials and postmarketing safety experience, and examines how this information can be used to optimize therapy.
Collapse
Affiliation(s)
- L Kunkel
- Genentech, Inc, South San Francisco, CA, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Saleh MN, Gutheil J, Moore M, Bunch PW, Butler J, Kunkel L, Grillo-López AJ, LoBuglio AF. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000; 27:99-103. [PMID: 11226008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
We conducted a prospective pilot phase I/II clinical trial to evaluate the toxicity and response rate of the chimeric anti-CD20 monoclonal antibody, rituximab (Rituxan; Genentech, Inc, South San Francisco, CA, and IDEC Pharmaceutical Corporation, San Diego, CA), in the treatment of patients with immune thrombocytopenic purpura. Patients with a clinical diagnosis of idiopathic thrombocytopenic purpura who had failed corticosteroid therapy and whose platelet count was less than 75,000/microL were eligible for the study. Rituximab was administered in a dose-escalation fashion using doses ranging from 50 to 375 mg/m2 weekly for 4 weeks. Thirteen patients have been enrolled on the trial to date and 12 have completed the full course of treatment. No unusual toxicity was noted in this patient population. None of the three patients at the lowest dose level achieved a clinical response. Three of nine patients (30%) who have received rituximab at doses close or equal to the full dose have shown an objective clinical response (two complete responses, one partial response). The study is currently ongoing, and conclusions regarding the overall response rate, clinical parameters that influence response, surrogate markers of response, and the underlying mechanism of response remain to be addressed. The current study should provide answers to a number of important questions regarding the role of rituximab in the treatment of this and other autoimmune disorders.
Collapse
MESH Headings
- Adult
- Aged
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/adverse effects
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/adverse effects
- Antineoplastic Agents/therapeutic use
- Clinical Protocols
- Combined Modality Therapy
- Dose-Response Relationship, Drug
- Female
- Humans
- Male
- Middle Aged
- Pilot Projects
- Purpura, Thrombocytopenic, Idiopathic/drug therapy
- Purpura, Thrombocytopenic, Idiopathic/surgery
- Rituximab
- Splenectomy
Collapse
Affiliation(s)
- M N Saleh
- University of Alabama at Birmingham, USA
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Perls T, Shea-Drinkwater M, Bowen-Flynn J, Ridge SB, Kang S, Joyce E, Daly M, Brewster SJ, Kunkel L, Puca AA. Exceptional familial clustering for extreme longevity in humans. J Am Geriatr Soc 2000; 48:1483-5. [PMID: 11083328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
Four families highly clustered for extreme longevity are described here, representing the first report of clustering for this phenotype. Families such as these may prove to be helpful in the further understanding of the genetic contribution to achieving exceptional longevity.
Collapse
Affiliation(s)
- T Perls
- Gerontology Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Perls T, Terry DF, Silver M, Shea M, Bowen J, Joyce E, Ridge SB, Fretts R, Daly M, Brewster S, Puca A, Kunkel L. Centenarians and the genetics of longevity. Results Probl Cell Differ 2000; 29:1-20. [PMID: 10838692 DOI: 10.1007/978-3-540-48003-7_1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Affiliation(s)
- T Perls
- Gerontology Division, Beth Israel Deaconess Medical Center, Harvard Division on Aging, Boston, MA 02215, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6 Suppl 1:S11-4. [PMID: 10685652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
PURPOSE To update response duration and survival data for patients with metastatic melanoma receiving the high-dose IV bolus recombinant interleukin (IL)-2 regimen. PATIENTS AND METHODS Two hundred seventy assessable patients were entered into eight clinical trials conducted between 1985 and 1993. IL-2 600,000 or 720,000 IU/kg was administered by 15-minute intravenous infusion every 8 hours for up to 14 consecutive doses over 5 days as clinically tolerated with maximum support, including pressors. A second, identical cycle of treatment was scheduled following 6 to 9 days of rest, and courses could be repeated every 6 to 12 weeks in stable or responding patients. Responding patients received up to five courses (two cycles/course) of treatment. All data were updated through December 1998 using report forms completed by the clinical investigators. RESULTS The objective overall response rate was unchanged from the previous report. Tumor responses were seen in 16% of patients, with complete responses in 17 (6%) and partial responses in 26 (10%). Median survival for the group as a whole is now 12 months. Median follow-up time for surviving patients exceeds 7 years. Median duration of response for the 43 responding patients and the 26 patients with partial responses remained unchanged at 8.9 and 5.9 months, respectively. Response durations ranged from 1.5 to > 122 months. The median duration of complete responses has yet to be reached, but is at least 59 months. Thirty-one patients (11%) were alive as of last contact; 28 were confirmed, including 18 responding patients. Three patients were lost to follow-up at > 1, > 13, and > 104 months. Twelve responding patients remained continually disease- or progression-free from > 70 to > 150 months following initiation of therapy. Disease progression was not observed in any patient who was responding as of the last report or in any patient responding for longer than 30 months. CONCLUSION These data continue to support the notion that high-dose IL-2 produces durable responses in some patients with metastatic melanoma and should be considered a therapeutic option for appropriately selected patients with this disease.
Collapse
Affiliation(s)
- M B Atkins
- Cytokine Working Group, Harvard University, Boston, Massachusetts, USA
| | | | | | | |
Collapse
|
31
|
Grillo-López AJ, Kunkel L. Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999. Clin Cancer Res 2000; 6:317-8. [PMID: 10656464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
|
32
|
Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-16. [PMID: 10561265 DOI: 10.1200/jco.1999.17.7.2105] [Citation(s) in RCA: 1410] [Impact Index Per Article: 56.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
PURPOSE To determine the short- and long-term efficacy and toxicity of the high-dose intravenous bolus interleukin 2 (IL-2) regimen in patients with metastatic melanoma. PATIENTS AND METHODS Two hundred seventy assessable patients were entered onto eight clinical trials conducted between 1985 and 1993. IL-2 (Proleukin [aldesleukin]; Chiron Corp, Emeryville, CA) 600,000 or 720,000 IU/kg was administered by 15-minute intravenous infusion every 8 hours for up to 14 consecutive doses over 5 days as clinically tolerated with maximum support, including pressors. A second identical treatment cycle was scheduled after 6 to 9 days of rest, and courses could be repeated every 6 to 12 weeks in stable or responding patients. Data were analyzed through fall 1996. RESULTS The overall objective response rate was 16% (95% confidence interval, 12% to 21%); there were 17 complete responses (CRs) (6%) and 26 partial responses (PRs) (10%). Responses occurred with all sites of disease and in patients with large tumor burdens. The median response duration for patients who achieved a CR has not been reached and was 5.9 months for those who achieved a PR. Twelve (28%) of the responding patients, including 10 (59%) of the patients who achieved a CR, remain progression-free. Disease did not progress in any patient responding for more than 30 months. Baseline performance status and whether patients had received prior systemic therapy were the only predictive prognostic factors for response to IL-2 therapy. Toxicities, although severe, generally reversed rapidly after therapy was completed. Six patients (2%) died from adverse events, all related to sepsis. CONCLUSION High-dose IL-2 treatment seems to benefit some patients with metastatic melanoma by producing durable CRs or PRs and should be considered for appropriately selected melanoma patients.
Collapse
Affiliation(s)
- M B Atkins
- Cytokine Working Group and Surgery Branch, National Cancer Institute, Bethesda, MD, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
Health care reform goals are to reduce costs and increase access while maintaining quality of care. A potentially effective avenue for achieving these difficult goals is to activate the untapped potential of consumers in managing their own health care. This study focuses on three Northwest communities and examines the prevalence of the use of self-care resources and the correlates of use. A random sample of households was surveyed using a mail-out questionnaire. The findings indicated that the use of self-care resources was high in the three community populations. Consulting a self-care book was the most commonly used resource, followed by telephone advice nurses. Communities do vary in their level of self-care resource use. Understanding this variability may help communities to expand the use of such resources and lessen the demand for formal health care services. Suggestions for future studies are discussed.
Collapse
Affiliation(s)
- J H Hibbard
- Department of Planning, Public Policy & Management, University of Oregon, Eugene 97403-1209, USA.
| | | | | | | | | |
Collapse
|
34
|
Kunkel L. Caveolin-3 deficiency as a cause of limb-girdle muscular dystrophy. J Child Neurol 1999; 14:33-4. [PMID: 10223848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Affiliation(s)
- L Kunkel
- Children's Hospital and Harvard University, Boston, MA, USA
| |
Collapse
|
35
|
Chabannon C, Cornetta K, Lotz JP, Rosenfeld C, Shlomchik M, Yanovitch S, Marolleau JP, Sledge G, Novakovitch G, Srour EF, Burtness B, Camerlo J, Gravis G, Lee-Fischer J, Faucher C, Chabbert I, Krause D, Maraninchi D, Mills B, Kunkel L, Oldham F, Blaise D, Viens P. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. Br J Cancer 1998; 78:913-21. [PMID: 9764583 PMCID: PMC2063121 DOI: 10.1038/bjc.1998.601] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Seventy-one patients with poor-prognosis breast cancer were enrolled after informed consent in a multicentre randomized study to evaluate the use of selected peripheral blood CD34+ cells to support haematopoietic recovery following high-dose chemotherapy. Patients who responded to conventional chemotherapy were mobilized with chemotherapy (mainly high-dose cyclophosphamide) and/or recombinant human granulocyte colony-stimulating factor (rhG-CSF). Patients who reached the threshold of 20 CD34+ cells per microl of peripheral blood underwent apheresis and were randomized at that time to receive either unmanipulated mobilized blood cells or selected CD34+ cells. For patients in the study arm, CD34+ cells were selected from aphereses using the Isolex300 device. Fifteen patients failed to mobilize peripheral blood progenitors and nine other patients were excluded for various reasons. Forty-seven eligible patients were randomized into two comparable groups. CD34+ cells were selected from aphereses in the study group. Haematopoietic recovery occurred at similar times in both groups. No side-effect related to the infusion of selected cells was observed. The frequency of epithelial tumour cells in aphereses was low (8 out of 42 evaluated patients), as determined by immunocytochemistry. We conclude that selected CD34+ cells safely support haematopoietic recovery following high-dose chemotherapy in patients with poor-prognosis breast cancer.
Collapse
Affiliation(s)
- C Chabannon
- Institut Paoli-Calmettes, Marseilles, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
In an effort to reduce the risk of opportunistic infections, 25 patients with advanced indolent lymphoma (age range: 30-77 years) were treated, using a combination of fludarabine and mitoxantrone, without corticosteroids. Fludarabine was given at 25 mg/m2 for three daily doses, and mitoxantrone at 10 mg/m2. Cycles were repeated every four weeks for up to maximum response, and for no more than six months. Eight patients had follicular lymphoma, and 11 had CLL/SLL. Objective response was observed in 11 of 12 previously untreated patients, including five complete remissions, and in 10 of 13 previously treated patients, including three complete remissions. Only two relapsed patients failed to respond, whereas two patients were not evaluable. Hence, the overall response rate based on the intention-to-treat analysis was 84 per cent (95 per cent CI: 70-98 per cent). The median survival has not been reached after a 22-month follow-up. Median time to progression was 15 months. One patient on corticosteroids developed pneumocystis carinii pneumonia, and an elderly patient succumbed to neutropenic sepsis. Apart from granulocytopenia, the treatment was well tolerated. Omission of corticosteroids reduces the risk of opportunistic infections, while the activity of the combination against indolent lymphoma and CLL is maintained.
Collapse
|
37
|
Bönnemann C, Wong J, Hamida CB, Hamida MB, Hentati F, Kunkel L. LGMD 2E in Tunisia is caused by a missense mutation Arg91Leu in β-sarcoglycan. Neuromuscul Disord 1997. [DOI: 10.1016/s0960-8966(97)87298-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
38
|
Thompson AA, Talley JA, Do HN, Kagan HL, Kunkel L, Berenson J, Cooper MD, Saxon A, Wall R. Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. Blood 1997; 90:1387-94. [PMID: 9269755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Leukemic B cells in chronic lymphocytic leukemia (B-CLL) typically exhibit low or undetectable surface Ig. Because the B29 (CD79b and Ig beta) and mb-1 (CD79a and Ig alpha) gene products are required for surface Ig display in the B-cell receptor complex (BCR), we analyzed the expression of these genes in B-CLL cells. The majority (83%) of the randomly selected B-CLL patient samples analyzed exhibited low or undetectable surface BCR measured by mu heavy chain and B29 expression. Levels of mb-1 mRNA in these B-CLL samples with low surface BCR were similar to those in normal B cells. Among those with decreased surface expression, B29 mRNA was not detected in half of these B-CLL samples. The remaining B-CLL samples with diminished surface BCR contained normal levels of B29 mRNA. Further analysis of cDNA clones from the majority of these latter samples contained point mutations, insertions, or deletions that were largely located in the B29 transmembrane and cytoplasmic domains. These results indicate the occurrence of somatic mutations predicted to affect B29 expression and/or function in the majority of B-CLL and suggest that these aberrations underlie the diminished surface BCR display and loss of BCR signaling characteristic of this leukemia.
Collapse
MESH Headings
- Antigens, CD/analysis
- Antigens, CD/genetics
- B-Lymphocytes/immunology
- CD79 Antigens
- Cell Separation
- Chromosome Aberrations
- Cloning, Molecular
- Flow Cytometry
- Humans
- Immunoglobulin mu-Chains/analysis
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Mutation
- RNA, Messenger/analysis
- Receptors, Antigen, B-Cell/analysis
- Receptors, Antigen, B-Cell/genetics
Collapse
Affiliation(s)
- A A Thompson
- Department of Pediatrics, UCLA School of Medicine and The Molecular Biology Institute, UCLA, Los Angeles, CA 90095, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L, Hawkin RA, Maddahi J, Phelps ME. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38:343-8. [PMID: 9074514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
UNLABELLED Accurate staging of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) is important for treatment management. In this study, the utility of 2-[18F]fluoro-2-deoxy-D-glucose (FDG) whole-body PET was evaluated as an imaging modality for initial staging or restaging of 7 HD and 11 NHL patients. METHODS Whole-body PET-based staging results were compared to the patient's clinical stage based on conventional staging studies, which included combinations of CT of the chest, abdomen and pelvis, MRI scans, gallium scans, lymphangiograms, staging laparatomies and bone scans. RESULTS Accurate staging was performed in 17 of 18 patients using a whole-body PET-based staging algorithm compared to the conventional staging algorithm in 15 of 18 patients. In 5 of 18 patients, whole-body PET-based staging showed additional lesions not detected by conventional staging modalities, whereas conventional staging demonstrated additional lesions in 4 of 18 patients not detected by whole-body PET. The total cost of conventional staging was $66,292 for 16 CT chest scans, 16 CT abdominal/pelvis scans, three limited MRI scans, four bone scans, five gallium scans, two laparotomies and one lymphangiogram. In contrast, scans cost $36,250 for 18 whole-body PET studies and additional selected correlative studies: one plain film radiograph, one limited CT, one bone marrow scan, one upper GI and one endoscopy. CONCLUSION A whole-body FDG-PET-based staging algorithm may be an accurate and cost-effective method for staging or restaging HD and NHL.
Collapse
Affiliation(s)
- C K Hoh
- Department of Molecular and Medical Pharmacology, Crump Institute of Biological Imaging, Los Angeles, California, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Paquette RL, Yoshimura R, Veiseh C, Kunkel L, Gajewski J, Rosen PJ. Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1997; 96:92-7. [PMID: 9012693 DOI: 10.1046/j.1365-2141.1997.d01-1984.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Seven patients with paroxysmal nocturnal haemoglobinuria (PNH) were treated with antithymocyte globulin (ATG). Each patient received ATG (20 mg/kg/d) for 8 d and prednisone to prevent or control serum sickness. Three patients experienced a sustained improvement in at least one peripheral blood cytopenia, including one patient who had a complete trilineage response. Several pretreatment clinical features appeared to be associated with response to ATG. All responding patients had hypoproliferative features including depressed platelet counts (< 30 x 10(9)/l), and a minor degree of chronic haemolysis as indicated by relatively low reticulocyte counts (< 100 x 10(9)/l), lactate dehydrogenase (< 1000 U/l) and total bilirubin (< 17 mumol/l) levels. Responding patients continued to have chronic low-grade haemolysis after their response to immunosuppression that was similar to that observed prior to treatment. The non-responding patients had a classic haemolytic form of PNH characterized by elevated reticulocyte counts (> 100 x 10(9)/l), lactate dehydrogenase (> 2000 U/l) and total bilirubin (> 17 mumol/l) levels. The impaired haemopoiesis that occurs in hypoproliferative PNH may respond to ATG treatment, but the haemolytic component of the disease, and hence the PNH clone, is not altered by immunosuppressive therapy.
Collapse
|
41
|
Guo WX, Antakly T, Cadotte M, Kachra Z, Kunkel L, Masood R, Gill P. Expression and cytokine regulation of glucocorticoid receptors in Kaposi's sarcoma. Am J Pathol 1996; 148:1999-2008. [PMID: 8669484 PMCID: PMC1861631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Development of Kaposi's sarcoma (KS) after glucocorticoid therapy has been observed in a variety of clinical states including human immunodeficiency virus-1 infection and recent in vitro studies provided evidence for a direct stimulation effect of glucocorticoid hormones on KS cell proliferation. The importance of glucocorticoids in KS pathogenesis is further highlighted by the finding that glucocorticoids synergize with cytokines to promote acquired immune deficiency syndrome (AIDS)-associated KS (AIDS-KS) growth. Furthermore, cytokine effects were abrogated by the glucocorticoid antagonist RU-486. As glucocorticoid action is mediated through activation of their intracellular cognate receptors, we hypothesized that enhanced responsiveness of AIDS-KS cells to glucocorticoids may be due to elevated glucocorticoid receptor (GR) content. Indeed, high expression of GRs in AIDS-KS tumor biopsies was detected both at the level of mRNA and protein. Quantitative measurements of GRs in these specimens by a sensitive immunoassay showed that GR content was significantly elevated in the tumor tissue (4663 fmol/mg protein) compared with the uninvolved skin of the same patients (2777 fmol/mg protein), both of which were markedly above the normal skin of healthy donors (893 fmol/mg protein). Immunocytochemical analysis confirmed the presence of GRs in the cytoplasm and the nucleus of KS cells. Interestingly, four major KS cytokines, namely interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, and oncostatin M, all of which are known autocrine growth factors for AIDS-KS cells, significantly increased the expression of functional GRs in cultured AIDS-KS cells. The latter result may explain, at least in part, the synergistic effect of glucocorticoid and oncostatin M on AIDS-KS cell proliferation. Thus, the high levels of GR expression in AIDS-KS and the up-regulation of GRs by KS-growth-promoting factors may confer enhanced and sustained sensitivity to the stimulatory effects of glucocorticoids. The data presented also provide molecular bases for therapeutic interventions targeting GRs in this disease.
Collapse
Affiliation(s)
- W X Guo
- Department of Pathology, University of Montreal, Canada
| | | | | | | | | | | | | |
Collapse
|
42
|
Mendoza E, Territo M, Schiller G, Lill M, Kunkel L, Wolin M. Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1995; 15:299-303. [PMID: 7773222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
We studied 23 consecutive patients, median age 34 years, with relapsed or resistant aggressive lymphoma who underwent allogeneic BMT at the UCLA Medical Center Bone Marrow Transplantation Unit from 1 November 1984 to 30 March 1993. All patients were < 50 years of age and had sibling donors who were matched at the HLA-A, B and DR loci. Nine patients had Hodgkin's disease (HD) and 14 had non-Hodgkin's lymphoma (NHL); three of these had low grade histology and 11 had intermediate or high grade lymphoma histology. After a median follow-up of 34 months, eight patients are alive, seven without recurrent lymphoma. Five patients had early deaths. The disease-free survival for the entire group is 26% with an overall survival of 29%. There was no difference in survival rate on the basis of disease or histology. Comparing preparative regimens containing TBI to those without there was no difference in survival rate (P = 0.35). Neither age nor sex was a significant determinant of outcome (P = 0.63 and 0.36, respectively). Disease status at the time of transplantation proved to be the important determinant of outcome. Patients transplanted with chemotherapy sensitive disease (n = 9), defined as a partial or complete response to salvage chemotherapy, had a survival rate of 42%, which was significantly better than those who had refractory disease at transplantation (n = 14), who had a survival rate of 21% (P = 0.006). However, this small, but significant fraction of patients with refractory disease was curable. Thus, our data demonstrate that allogeneic bone marrow transplantation is an effective means of treatment for relapsed or aggressive Hodgkin's and non-Hodgkin's lymphoma.
Collapse
Affiliation(s)
- E Mendoza
- Department of Medicine, UCLA School of Medicine 90024, USA
| | | | | | | | | | | |
Collapse
|
43
|
|
44
|
Tschirhart DL, Kunkel L, Shulman IA. Immune hemolytic anemia associated with biclonal cold autoagglutinins. Vox Sang 1990; 59:222-6. [PMID: 1705735 DOI: 10.1111/j.1423-0410.1990.tb00241.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A 65-year-old man with bladder outlet obstruction due to prostatic hypertrophy was incidentally discovered to have cold-antibody autoimmune hemolytic anemia (cold-aggluthinin syndrome; CAS) due to autoanti-I (titer 1,024 at 4 degrees C and 64 at 30 degrees C), and a biclonal gammopathy. Immunofixation electrophoresis of serum and a red blood cell eluate revealed the patient's autoantibody to be biclonal IgM kappa and IgA kappa. No underlying cause could be determined to explain the development of either the biclonal gammopathy or the CAS. To our knowledge, this is the first reported case of CAS associated with a biclonal gammopathy and biclonal cold autoagglutinins of the IgM kappa, IgA kappa type.
Collapse
Affiliation(s)
- D L Tschirhart
- Los Angeles County, University of Southern California Medical Center
| | | | | |
Collapse
|
45
|
Tschirhart DL, Kunkel L, Shulman IA. Immune Hemolytic Anemia Associated with Bidonai Cold Autoagglutinins. Vox Sang 1990. [DOI: 10.1159/000461213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
46
|
Abstract
Individual translocation chromosomes from six girls suffering from Duchenne or Becker muscular dystrophy (DMD or BMD) have been isolated in human-mouse somatic cell hybrids. DNA prepared from these hybrids was probed with sequences physically close to the locus; these include a junction fragment from the site of the X:21 translocation (pXJ1) and subclones from the pERT 87 (DXS164) region which are absent in a minority of male DMD patients. Both sets of sequences mapped within the area defined by the translocation breakpoints, confirming their close proximity to the DMD and BMD loci. Furthermore, the X chromosome breakpoints of the translocations can be divided into three categories depending upon their position in relation to the sequences recognised by pXJ1 and pERT 87. The genomic target disrupted by the translocations examined here is a minimum of 176 kb.
Collapse
|
47
|
|
48
|
Kwan SP, Kunkel L, Bruns G, Wedgwood RJ, Latt S, Rosen FS. Mapping of the X-linked agammaglobulinemia locus by use of restriction fragment-length polymorphism. J Clin Invest 1986; 77:649-52. [PMID: 3003164 PMCID: PMC423409 DOI: 10.1172/jci112351] [Citation(s) in RCA: 99] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
A molecular linkage analysis in 11 families with X-linked agammaglobulinemia (XLA) localized the XLA gene to the proximal part of the long arm of the human X chromosome. Significant linkage was detected between XLA and loci defined by two polymorphic DNA probes called 19-2 for the DXS3 locus and S21 for the DXS17 locus. Both localize to the region Xq21.3-Xq22. Most likely recombination distances (theta) and associated logarithm of the odds (lod) scores for the XLA-DXS3 and XLA-DXS17 pairs were theta = 0.04 morgans (lod, 3.65) and theta = 0 (lod, 2.17), respectively. Tight linkage between XLA and the locus DXS43 defined by the X short arm probe D2 (localized to Xp22-Xp21) was strongly excluded and we obtained no evidence for significant linkage between XLA and any other X short arm probe. The probe pair 19-2 and S21 should be informative for molecular linkage-based analysis of XLA segregation in the majority of families afflicted with this disorder.
Collapse
|
49
|
Bertram JH, Grunberg SM, Shulman I, Apuzzo ML, Boquiren D, Kunkel L, Hengst JC, Nelson J, Waugh WJ, Plotkin D. Staphylococcal Protein A column: correlation of mitogenicity of perfused plasma with clinical response. Cancer Res 1985; 45:4486-94. [PMID: 4028030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Eleven patients with advanced breast cancer and four with astrocytoma were treated with plasma perfused over columns containing staphylococcal Protein A (SPA). Doses of 5 to 20 mg of SPA were bound to collodion charcoal particles, and this treatment resulted in partial remissions in one patient with astrocytoma and in two patients with breast cancer. Remission duration was 6 wk to 6 mo. Resolution of lymphadenopathy and a decrease in carcinoembryonic antigen were noted in an additional two breast cancer patients. Systemic reactions to infused plasma consisted of fever, chills, and rigors. In brain cancer patients, increased intracranial pressure was also noted. A mitogenic substance was generated in plasma of 11 patients after it was perfused over the SPA charcoal matrix. The mitogenic material induced lymphoproliferation comparable to concanavalin A and required the presence of SPA on the collodion charcoal but was not due to leakage of SPA from the column during plasma perfusion. Of considerable significance was that only patients whose column perfused plasma contained this mitogenic activity exhibited systemic reactions, and five of these patients obtained antitumor responses. This striking correlation implies that the mitogenic factor is an active component of SPA therapy. The ability to demonstrate mitogenicity in column perfused plasma might also be useful for selecting patients amenable to SPA therapy. These findings attest to the therapeutic value of this mode of treatment and provide an initial definition of a mediator of SPA antitumor activity.
Collapse
|
50
|
Brown CS, Thomas NS, Sarfarazi M, Davies KE, Kunkel L, Pearson PL, Kingston HM, Shaw DJ, Harper PS. Genetic linkage relationships of seven DNA probes with Duchenne and Becker muscular dystrophy. Hum Genet 1985; 71:62-74. [PMID: 2993158 DOI: 10.1007/bf00295671] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The inheritance of seven restriction fragment length polymorphisms detected by DNA probes has been studied in families with Duchenne and Becker muscular dystrophies (DMD and BMD). The probes used have all been mapped to the short arm of the X-chromosome, four being distal and three proximal to the disease loci located within the Xp21 region. Linkage analysis of the DNA polymorphisms in relation to the two disorders showed similar genetic distances. Data obtained from DMD and BMD families have been combined to give more precise values for the different recombination fractions. Combined use of these polymorphic DNA markers will be of practical value in the genetic counselling of women at risk for Duchenne and Becker muscular dystrophy.
Collapse
|